Acadian Asset Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Acadian Asset Management’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-696,740	Closed	-$371K	–	1862
2024 Q4	$371K	Sell	696,740 -213,601	-23%	-$149K	﹤0.01%	1139
2024 Q3	$1.6M	Buy	910,341 +214,369	+31%	+$299K	0.01%	809
2024 Q2	$813K	Buy	+695,972	New	+$1.74M	﹤0.01%	1064
2023 Q1	–	Sell	-7,041	Closed	-$28K	–	2023
2022 Q4	$28K	Buy	+7,041	New	+$34.6K	﹤0.01%	1668
2019 Q2	–	Sell	-5,872	Closed	-$98K	–	2086
2019 Q1	$98K	Buy	+5,872	New	+$84.5K	﹤0.01%	1528
2017 Q3	–	Sell	-1,082	Closed	-$6K	–	1564
2017 Q2	$6K	Buy	+1,082	New	+$5.85K	﹤0.01%	1365

Acadian Asset Management's MRNS Position: Q1 2025 in Review

Acadian Asset Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 696,740 shares — an estimated $371K sold.

Acadian Asset Management first reported a position in MRNS in Q2 2017 and held it in 6 quarters. The position peaked at $1.6M in Q3 2024. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.

Acadian Asset Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
Acadian Asset Management sold 696,740 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $371K.
Acadian Asset Management first reported a position in Marinus Pharmaceuticals, Inc in Q2 2017 and held it in 6 quarters.
Acadian Asset Management's Marinus Pharmaceuticals, Inc position peaked at $1.6M in Q3 2024.
0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.

Based on Acadian Asset Management's 13F filing for Q1 2025, filed 21 May 2025.